Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
MRD Outcomes From CEPHEUS at ASH 2024
Saad Z. Usmani, MD, MBA, FACP, discusses how the CEPHEUS study, presented at ASH 2024, along with its expanded analysis of minimal residual disease (MRD) outcomes, provides valuable insights into the role of MRD as a biomarker in multiple myeloma treatment, highlighting its potential to guide therapy decisions and improve patient outcomes.
EP: 1.Early Intervention in High-Risk Smoldering Myeloma: Results From the AQUILA Study at ASH 2024
EP: 2.Exploring the Frontline Potential of Teclistamab: Insights From MajesTEC-5 at ASH 2024
Now Viewing
EP: 3.MRD Outcomes From CEPHEUS at ASH 2024
EP: 4.Transplant-Ineligible Myeloma and MRD Integration: Current Definitions and Future Directions
Video content above is prompted by the following:
- Provide a brief overview of the CEPHEUS study and the expanded analysis of MRD outcomes presented at ASH 2024.
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What additional MRD outcomes were presented?
Related Videos
Related Content
ICYMI: Highlights From AMCP Nexus 2024
December 26th 2024Article
Check out this year's top coverage from The Academy of Managed Care Pharmacy (AMCP) Nexus 2024 meeting, which included relevant topics in health care policy, novel pharmaceutical developments, financial considerations across multiple conditions, and more.
Read More
